Insulet Corporation paid $25 million for assets related to Bigfoot Biomedical’s pump-based automated insulin delivery technologies. The acquisition includes certain Bigfoot patents related to pumps that may be used for automated insulin delivery therapy.
Bigfoot Biomedical is a leader in developing intelligent connected injection support systems.
Insulet is a medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform.
According to data captured in the LevinPro HC database, this acquisition represents the second remote patient monitoring (RPM) deal of 2023. There were 15 RPM transactions in 2022.
